Latest news and information from STADA, Thornton & Ross.

news image Find out more
22/07/2024

UZPRUVO▼ STADA's ustekinumab biosimilar is now available

As part of STADA’s commitment to caring for people’s health and supporting the NHS in its mission to provide high quality healthcare to all patients across the UK, we have now entered the global biosimilar pipeline for immunology.

Prescribing information can be found here.

news image Find out more
05/06/2024

STADA UK set for Kidney Week Symposium following successful Kinpeygo 4mg▼ (modified-release hard capsules budesonide) launch and patients starting treatment

Edinburgh International Conference Centre will see Nephrology experts discuss how best to advance the care of UK IgAN patients on 12 June, with a special event organized by STADA UK as part of UK Kidney Week.

Professor Daniel Gale, St Peter’s Chair of Nephrology, and Chee Kay Cheung, Consultant Nephrologist, will take part in a panel discussion titled ‘Advancing the Care of IgAN Patients in the UK’ sponsored by STADA UK.

Prescribing Information can be found here

news image Find out more
08/02/2024

Press Release: STADA UK welcomes NICE recommendation of Kinpeygo® 4mg▼ (modified-release hard capsules budesonide)

First-ever NICE guidance on treating primary IgA nephropathy recommends Kinpeygo® (modified-release hard capsules budesonide) capsules as “an acceptable use of NHS resources” in England and Wales.

Find out more about Kinpeygo® (modified-release hard capsules budesonide) – request a visit from our Medical Science Liaison Team or Healthcare Partnership Manager Team by clicking here

Prescribing Information can be found here

news image Find out more
10/01/2024

New NICE Guidance on targeted-release budesonide for primary IgA nephropathy

Read the latest NICE guidance today

Prescribing Information can be found here

news image Find out more
15/09/2023

Read our summary of all the latest guidance on the use of ranibizumab, including NHS England's August updates

An overview of the latest NHS England recommendations and other guidance supporting the adoption of ranibizumab biosimilars.

news image Find out more
31/08/2023

STADA Specialty Care

Discover more about a rapidly expanding portfolio of high-quality biosimilar medicines

Information

For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics

Adverse events should be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164. Additionally, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.

UK-MULT-122c(6) | July 2024

This site is intended to provide information to Healthcare Professionals on Thornton & Ross products.

I am a UK Healthcare Professional

Yes     No

The information on our Healthcare Professional Website is solely intended for UK Healthcare Professionals and contains promotional information. Click here to return to our main public site.

For information on our products please visit EMC and search the product for a Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.